News

Deocrative graphic with beanstalk and sun

Synthetic proteins are being built with the help of AI models

Others are taking a slightly different tack. Profluent, in Emeryville, California and EvolutionaryScale, in New York, are building protein-design AI models that resemble not image-generating software, but large language models (LLMs) of the sort that power the world’s chatbots. These firms’ models treat the amino-acid sequences in protein chains like the words in a piece of text—analysing relationships found in zillions of exemplars to design novel useful structures. According to Ali Madani, Profluent’s chief executive, the firm is particularly focused on creating new CRISPR-Cas gene-editing tools. Here, its USP is a curated database of around 5m CRISPR-Cas protein complexes on which its AI model has been trained in order to design new versions.

Latest news190

Banksy Tags Bakar Bio Labs

Since the 60’s, Berkeley has been home of free expression, though never through graffiti. But Gino Segre, MD, was surprised to found a crowd had formed near the front entrance of Bakar BioEnginuity Hub Tuesday morning. Students, faculty, and other passersby numbering in the dozens were staring at unauthorized artwork painted on the front facade of the Brutalist landmark building. The installation provoked varied responses, many nodding vigorously that it was vibrant, bold, profane, and timely. An employee pressed through the crowd on her way into work, and muttered it looked like her recently contaminated cell culture. Read post
Oki O'Connor, Michael Kope, Amelia Anderson

How Cyclarity Therapeutics is Taking On the World’s Leading Killer

You think you don’t know someone with atherosclerosis, but it’s likely you actually do. Atherosclerosis is the build-up of oxidized cholesterol in arteries, an underlying factor in an astonishing 50% of deaths in Western society. An indicator of dementia, Alzheimer’s, heart disease, lung disease, and more, it’s one of the first detectable signs of aging. As co-founder and CEO of scientific affairs at Cyclarity Therapeutics, Matthew “Oki” O’Connor directs a team developing a drug to neutralize this killer. Oki’s potentially life-saving breakthrough came in the form of the least scientific experiment imaginable. In early 2018, he worked in Mountain View at the SENS Research Foundation, which is dedicated to finding cures for aging-related disease. It was on a quiet Friday night when everyone in the lab was either out sick, traveling, or home, that he decided to test out their first prototype. Read post
mother with her child in a farm

Verinomics Introduces Transgene-Free Gene Editing and Genomic-Driven Accelerated Breeding Platforms for Specialty Crops

Verinomics, a leader in agricultural genomics and gene editing, today unveiled two breakthrough platforms designed to accelerate specialty crop innovation: Genesis™, a transgene-free gene editing platform, primarily for vegetatively propagated crops and Genova™, a genomic-driven breeding acceleration platform for both seed and vegetatively propagated crops. Together, these technologies streamline trait discovery and product development, delivering high-value, market-ready crops faster than ever before. Read post
aikium

Breaking the ‘Undruggable’ Barrier with AI and Synthetic Biology: Eswar Iyer, CEO of Aikium

For decades, drug developers have struggled with so-called "undruggable" proteins—those regions of the proteome that evade traditional small molecules and antibodies. But Aikium, led by Eswar Iyer, could be changing the game. In today’s show, Iyer, a prolific scientist with over 100 patents and a background in George Church’s lab, shares how his company is tackling one of the toughest challenges in therapeutics. Read post
Charles Tait Graves

How Startups Can Minimize Risk in the Area of Trade Secrets

“Any nonpublic item of business information that could be valuable to a competitor is a trade secret,” Graves said. “Business details, product roadmaps, financial information, customer information, if it’s not public and if it would be useful for a competitor, it can be a trade secret. It doesn’t have to be strictly scientific and technical information.” Read post
The Futurebio team in the lab

Is a New Type of Plastic a Solution to the Climate Crisis? FutureBio, First Tenant in Bakar Climate Labs Pilot Program, Says Yes.

FutureBio is the first tenant in the pilot program at UC Berkeley’s new climate tech incubator: Bakar Climate Labs. Until the new incubator on the west side of campus opens in 2028, the pilot program is accepting startups leasing space at Bakar Bio Labs and the QB3 Garage incubator in Stanley Hall. But FutureBio isn’t waiting for the ink to dry on blueprints—they’re already moving forward, transforming the way we think about plastic and our planet’s future. Read post
bakar bio labs

We Are Now Bakar Bio Labs

We have a new name! And logo. As the larger Bakar Labs organization expands into multiple locations and adds the climate tech vertical, our goal is to keep our branding as clear as possible. So we are now Bakar Bio Labs, as you probably noticed. Going forward, the general “Bakar Labs” title will be reserved for the parent organization we fall under. Beneath the Bakar Labs umbrella there are two units: Bakar Bio Labs and Bakar Climate Labs, for which our pilot program is now live (the facility, on the west side of the UC Berkeley campus, will open in 2028). Bakar Bio Labs will operate at two locations: the original, at 2630 Bancroft Way in Berkeley, and a new UCSF building in development in the Dogpatch neighborhood in San Francisco. Read post
Marco Lobba, Rachel Haurwitz, and Wei Wu

Event Recap: “Working With Strategic Investors”

“Between all these investors and companies,” Haurwitz said, “I think it becomes very clear over time that different incentives drive different interactions.” She advises building personal relationships to find out how and why each fund makes investments: some for profit, some for strategic reasons (like licensing or later acquisition); sometimes both at the same fund. (Haurwitz was the first student to work on CRISPR in Jennifer Doudna’s lab, she said; traditional VCs had no interest in CRISPR while CVCs – Dupont first among them – were knocking on the door, quick to see the long-term potential.) Read post

At Biotech’s Biggest Conference, UC Berkeley Shows Off Startups

In a way, biotech startup Editpep’s story is one faced by many new life sciences companies in a tough funding environment; in a way, too, it is so Berkeley. Co-founded by University of California, Berkeley postdoctoral researcher looking at ways to cure genetic diseases, an MBA student and a scientific disciple of CRISPR gene-editing technology pioneer Jennifer Doudna, Editpep last month secured an $8.4 million seed financing to take on pediatric brain cancer and other brain diseases. Read post
sophia lugo

‘You have to believe that you can be a leader’: Sophia Lugo, NHI’s 2024 Person of the Year

Sophia Lugo has made a remarkable journey in her career so far, moving from Silva Magnet/Jefferson High School in El Paso to Harvard University for undergraduate studies on biology, the Schwarzman Scholars program at Tsinghua University for graduate studies in public policy, and Stanford University for her MBA, work with entities including the Boston Consulting Group and the Bill & Melinda Gates Foundation, eventually becoming co-founder and CEO of a company aiming to change medicine as we know it. Read post
incubator

What to Look for in a Biotech Incubator

Gino Segre, managing director of Bakar Labs, confirms that there is plenty you can look at to see if an incubator is successful. “Tenant occupancy relative to other incubators, fundraising success of the tenants over time, and word of mouth satisfaction are good indicators of the operating track record of the incubator.” Reaching out to former incubees to have direct feedback on their experience with the incubator is one of your strongest indicators if this is the right direction for you. Read post